Kidney sections from aged wild-type (left) and GzmK-deficient mice (right). Normal aging is associated with enlargement of the kidney’s filtering units (glomerular hypertrophy) and substantial deposition of inflammatory complement proteins (green). In mice lacking GzmK, both glomerular enlargement and complement deposition are markedly reduced, indicating protection against age-related kidney damage.
Image Credit: Nicole La Gruta
Scientific Frontline: Extended "At a Glance" Summary: Granzyme K and Age-Related Organ Damage
The Core Concept: Researchers have identified a specific protein, Granzyme K, that drives age-related cellular damage and scarring in vital organs, including the heart, liver, and kidneys.
Key Distinction/Mechanism: While Granzyme K is produced by immune cells, the study revealed that eliminating it protected organs from age-related deterioration without preventing the immune system itself from aging. This challenges the prevailing assumption that immune aging and organ damage are completely inseparable.
Origin/History: The research, published in Immunity on November 12, 2026, was conducted by scientists at the Monash Biomedicine Discovery Institute.
Major Frameworks/Components:
- Preclinical Models: Researchers compared aged wild-type mice with mice engineered to lack Granzyme K.
- Pathological Markers: The study observed reductions in fibrosis (scarring) and glomerular hypertrophy (enlargement of the kidney's filtering units), along with decreased inflammatory complement protein deposition in Granzyme K-deficient mice.
- Human Correlation: Analysis of human datasets showed elevated Granzyme K levels in patients with inflammatory and fibrotic conditions like lupus nephritis and heart failure.
Branches of Science: Immunology, Gerontology, Molecular Pathology, Hepatology, and Nephrology.
Future Application: The findings present a potential therapeutic target; developing drugs to selectively block Granzyme K later in life could prevent or slow down age-related organ decline and the onset of chronic diseases.
Why It Matters: Aging is a primary risk factor for chronic cardiovascular and renal diseases. Finding a mechanism to decouple immune aging from organ damage offers a promising strategy to help aging populations maintain healthier organ function and reduce disease vulnerability.
Monash University researchers have identified a protein that drives age-related pathological changes in vital organs, presenting a potential therapeutic target for mitigating age-associated tissue degradation.
Published in Immunity, the research uncovered a mechanistic link between the immune protein Granzyme K and senescence-related pathology in the heart, liver, and kidneys.
Granzyme K is produced by immune cells, and its circulating levels are known to increase significantly with age in both murine models and humans. However, its precise physiological role in age-related organ damage had previously remained uncharacterized.
The study, led by senior researcher Professor Nicole La Gruta at the Monash Biomedicine Discovery Institute, utilized preclinical murine models to compare aged wild-type mice with GzmK-deficient (knockout) cohorts.
The results demonstrated that mice lacking Granzyme K exhibited reduced organ pathology despite normal immune system senescence. This finding challenges the established paradigm that immune and organ aging are strictly interdependent.
In the GzmK-deficient cohorts, researchers observed significantly improved heart function and reduced fibrosis. These subjects also exhibited markedly reduced signs of age-related structural damage in their liver and kidneys.
In cross-referencing human clinical and transcriptomic datasets, the researchers found elevated levels of Granzyme K in patients with several inflammatory and fibrotic diseases, including lupus nephritis and heart failure.
Because aging is a primary risk factor for chronic conditions such as cardiovascular and kidney disease, limiting the accumulation of structural organ damage presents a viable strategy for reducing disease vulnerability.
The research team is currently investigating methodologies to selectively block Granzyme K in vivo. Because the knockout mice in the initial study lacked Granzyme K for their entire lifespans, subsequent clinical research will focus on determining whether targeting the protein pharmacologically later in life can achieve similar protective benefits.
Published in journal: Immunity
Authors: Dulakara Kannangara, Jessica Runting, April L. Raftery, Ekaterina Salimova, Xavier Y. X. Sng, Ali Zaid, Samantha J. Emery-Corbin, David Chisanga, Hui Xu, Angela Nguyen, Tania Camilleri, Joel A. Eliades, Zijian Huang, Iona S. Schuster, Ralf B. Schittenhelm, Phillip I. Bird, Laura Mackay, Kim L. Good-Jacobson, Adam J. Rose, Nicholas D. Huntington, Mariapia Degli-Esposti, Christopher T. Turner, Daniel Thiele, and Nicole L. La Gruta
Source/Credit: Monash University
Edited by: Scientific Frontline
Reference Number: imgy111326_01
